(Repeats to attach to corrected alerts)

Overview

* Amneal Q2 2025 net revenue rises 3% but misses analyst

expectations, per LSEG data

* Adjusted EBITDA for Q2 2025 increases 13% to $184 mln,

reflecting higher revenue and gross margin

* Co raises full year 2025 guidance, citing strong product

uptake

and FDA approval

Outlook

* Amneal raises 2025 adjusted EBITDA guidance to $665 mln -

$685

mln

* Company increases 2025 adjusted EPS forecast to $0.70 -

$0.75

* Amneal boosts 2025 operating cash flow outlook to $275 mln

-

$305 mln

* Company expects 2025 net revenue between $3.0 bln and $3.1

bln

Result Drivers

* SPECIALTY SEGMENT - Specialty net revenue rose 23% due to

strong

performance of branded products like CREXONT and RYTARY

* DEBT REFINANCING - Successful debt refinancing reduced

interest

costs and extended maturities, improving financial position

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $724.51 $744.60

Revenue mln mln (4

Analysts

)

Q2 Net $35.61

Income mln

Q2 Gross $286.25

Profit mln

Q2 $111.37

Operatin mln

g Income

Q2 $51.71

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy"

and

the breakdown of recommendations is 4 "strong buy" or "buy", no

"hold" and no "sell" or "strong sell"

* The average consensus recommendation for the

pharmaceuticals

peer group is "buy"

* Wall Street's median 12-month price target for Amneal

Pharmaceuticals Inc ( AMRX ) is $12.00, about 33.7% above its August 4

closing price of $7.96

* The stock recently traded at 10 times the next 12-month

earnings

vs. a P/E of 11 three months ago

Press Release:

(This story was created using Reuters automation and AI based

on LSEG and company data. It was checked and edited by a Reuters

journalist prior to publication.)